Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma

Autor: Dongyan Cai, Ting-Xun Lu, Hua-Qiang Gao, Tingting Hong, Xiaohong Wu, Ying Zhang, Hai-Ying Hua, Shuang Wu
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Cancer Research
Survival
Gastroenterology
0302 clinical medicine
International Prognostic Index
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Databases
Genetic
Non-Hodgkin lymphoma
Aged
80 and over
medicine.diagnostic_test
Diffuse large B-cell lymphoma
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
Immunohistochemistry
Oncology
B symptoms
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
Lymphoma
Large B-Cell
Diffuse
medicine.symptom
Research Article
Adult
Aspartic transaminase
medicine.medical_specialty
Adolescent
Subgroup analysis
lcsh:RC254-282
Young Adult
03 medical and health sciences
Internal medicine
Genetics
medicine
Humans
Aspartate Aminotransferases
Aged
Neoplasm Staging
Performance status
business.industry
Gene Expression Profiling
medicine.disease
030104 developmental biology
Liver function
business
Liver function tests
Biomarkers
Zdroj: BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
ISSN: 1471-2407
DOI: 10.1186/s12885-019-5758-2
Popis: Background Liver function is routinely assessed in clinical practice as liver function tests provide sensitive indicators of hepatocellular injury. However, the prognostic value of enzymes that indicate hepatic injury has never been systematically investigated in lymphoma, including diffuse large B-cell lymphoma (DLBCL). Methods This study examined the prognostic value of baseline aspartic transaminase (AST) in DLBCL patients. The association between AST and clinical features was analyzed in 179 DLBCL patients treated from 2006 to 2016. All enrolled patients were treated with R-CHOP or R-CHOP-like chemotherapy. Log-rank test, univariable analysis, and subgroup analysis were performed to evaluate the impact of AST on survival. Results AST 33.3 U/L was considered to be the optimal threshold value for predicting prognosis. A higher AST level was associated with advanced stage (P = 0.001), poorer performance status (P = 0.014), elevated lactate dehydrogenase level (P
Databáze: OpenAIRE
Externí odkaz: